SWOT

Budesonide in Primary Biliary Cholangitis Research Report 2024: Comprehensive Market Insights to 2032 with Focus on 7 Major Markets - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 5, 2024

The healthcare industry witnesses a significant milestone as the Budesonide Market Size, Forecast, and Drug Insight - 2032 report is introduced to the research inventory.

Key Points: 
  • The healthcare industry witnesses a significant milestone as the Budesonide Market Size, Forecast, and Drug Insight - 2032 report is introduced to the research inventory.
  • This latest analytical document delineates the progressive outlook of budesonide in treating primary biliary cholangitis (PBC), providing a detailed market forecast and insights into drug development and innovation within the pharmaceutical arena through to 2032.
  • Primary biliary cholangitis, a chronic liver disease, presents a therapeutic challenge, compelling industry stakeholders to eagerly explore new treatment avenues.
  • With a thorough research methodology encompassing secondary and primary data, industry expertise, and comprehensive market analysis, the report equips stakeholders with pivotal insights.

Complement Inhibitors (C3/C5) Market Poised for Significant Growth by 2034 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 5, 2024

The "Complement Inhibitors (C3/C5) Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Complement Inhibitors (C3/C5) Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.
  • Expanding at a Robust Pace, the Complement Inhibitors (C3/C5) Market Sees Advancements and Detailed Forecast
    The latest market research publication offers a comprehensive analysis of the Complement Inhibitors (C3/C5) market and its anticipated growth trajectory through 2034.
  • Through granular insights into the Complement Inhibitors (C3/C5) market, the report elucidates the potential for these therapies in improving patient care for those suffering from disorders linked to the complement system.
  • These insights are invaluable for stakeholders strategizing to navigate the complex and evolving Complement Inhibitors (C3/C5) market.

Global Bioplastics and Advanced Plastics Recycling Report 2024-2034: Market Challenges and Opportunities in Scaling Up Environment-friendly Solutions Aligned with Principles of Circular Economy - ResearchAndMarkets.com

Retrieved on: 
Monday, March 4, 2024

The "Global Market for Bioplastics and Advanced (Chemical) Plastics Recycling 2024-2034" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Market for Bioplastics and Advanced (Chemical) Plastics Recycling 2024-2034" report has been added to ResearchAndMarkets.com's offering.
  • Innovation in bioplastics and plastics recycling is spurring a renaissance in the petrochemical industry, with the latest technologies reinventing plastic and making waste plastic a new resource.
  • The Global Market for Bioplastics and Advanced (Chemical) Plastics Recycling 2024-2034 provides a comprehensive analysis of the global bio-based feedstocks, bio-based plastics, and advanced chemical recycling markets.
  • An extensive section is dedicated to the global bio-based and biodegradable plastics market, segmented by types including PLA, PHA, PBS, bio-PET etc.

United States HUMIRA Market Analysis, Size, Forecast, and Insights Report, 2019-2023 and 2024-2032 - ResearchAndMarkets.com

Retrieved on: 
Friday, March 1, 2024

The "US HUMIRA Market Size, Forecast, and Market Insight - 2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US HUMIRA Market Size, Forecast, and Market Insight - 2032" report has been added to ResearchAndMarkets.com's offering.
  • This report provides comprehensive insights about HUMIRA for autoimmune uveitis in the US.
  • Further, it also consists of future market assessments inclusive of the HUMIRA market forecast analysis for autoimmune uveitis in the US, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in autoimmune uveitis.
  • What are the other emerging products available and how are these giving competition to HUMIRA for autoimmune uveitis?

JARDIANCE Market Size, Forecast, and Emerging Insights, 2019-2023 and 2024-2032: Focus on 7MM - United States, Germany, France, Italy, Spain, United Kingdom, and Japan - ResearchAndMarkets.com

Retrieved on: 
Friday, March 1, 2024

Further, it also consists of future market assessments inclusive of the JARDIANCE market forecast analysis for myocardial infarction in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in myocardial infarction.

Key Points: 
  • Further, it also consists of future market assessments inclusive of the JARDIANCE market forecast analysis for myocardial infarction in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in myocardial infarction.
  • JARDIANCE (Empagliflozin) is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for glucose re-absorption in the kidney.
  • The report also highlights the JARDIANCE research and development activities in myocardial infarction across the United States, Europe and Japan.
  • A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of JARDIANCE in myocardial infarction.

Global Therapeutic Antibody Market Forecast to Reach USD 428.20 Billion by 2029: In-Depth Analysis by Antibody Type, Source, and Application - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 29, 2024

Global Therapeutic Antibody Market reveals significant insights into market segmentation, including monoclonal antibodies, bispecific antibodies, and more.

Key Points: 
  • Global Therapeutic Antibody Market reveals significant insights into market segmentation, including monoclonal antibodies, bispecific antibodies, and more.
  • This in-depth report examines the forecast growth trends and market dynamics from 2024 to 2029, with a specific focus on key regions and countries contributing to the global market expansion.
  • The market is analyzed by product type, source, and application, offering a thorough understanding of the therapeutic antibody landscape.
  • Through a careful examination of industry trends, drivers, and challenges, the report provides an insightful forecast and analysis that bolsters understanding of the Global Therapeutic Antibody Market's future trajectory.

Global Simulation and Analysis Market Set for Remarkable Growth: Advanced Technologies and End-use Applications Drive Momentum Through 2029 - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 29, 2024

The "Global Simulation and Analysis Market (2024 Edition): Analysis By Component (Software, Service) Deployment (On-Premise, Cloud), By End-use, By Region, By Country: Market Insights and Forecast (2024-2029)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Simulation and Analysis Market (2024 Edition): Analysis By Component (Software, Service) Deployment (On-Premise, Cloud), By End-use, By Region, By Country: Market Insights and Forecast (2024-2029)" report has been added to ResearchAndMarkets.com's offering.
  • This report presents detailed insight into this burgeoning sector, exploring several key facets of market evolution with a spotlight on innovative technologies and sector-specific applications.
  • It serves as an authoritative resource for those seeking to understand the future trajectory of the Simulation and Analysis industry through to the year 2029.
  • The latest analytical foray explores the Global Simulation and Analysis Market with a deep analytical lens, presenting data-driven insights into market segmentation by component, deployment, and varying end-uses.

Global Long Duration Energy Storage Industry Report 2023-2044: Materials, Equipment Markets, Technology Roadmaps, Manufacturers, Winners, Losers, Alternatives - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 28, 2024

The "Long Duration Energy Storage LDES Reality: Materials, Equipment Markets in 35 Lines, Technology Roadmaps, Manufacturers, Winners, Losers, Alternatives" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Long Duration Energy Storage LDES Reality: Materials, Equipment Markets in 35 Lines, Technology Roadmaps, Manufacturers, Winners, Losers, Alternatives" report has been added to ResearchAndMarkets.com's offering.
  • The Long Duration Energy Storage (LDES) report provides in-depth look at the future landscape of the industry – from materials and equipment markets to technology roadmaps, and company profiles.
  • The report delves into the reality of LDES, revealing potential winners and losers and exploring a wide array of alternatives through analytical forecasts stretching from 2024 to 2044.
  • Similar in-depth analysis is provided for other storage technologies like Compressed Air Energy Storage (CAES), Chemical Intermediary LDES (hydrogen, ammonia, methane), and Pumped Hydro Storage.

Aromatase Inhibitors (AIs) Market Size, Target Population, Competitive Landscape & Market Forecasts, 2020-2023 and 2024-2034 with Focus on 7 Major Markets - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 28, 2024

The "Aromatase Inhibitors (AIs) Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Aromatase Inhibitors (AIs) Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.
  • The Aromatase Inhibitors (AIs) market report provides insights around existing treatment practices in patients with Aromatase Inhibitors (AIs), approved (if any) and emerging Aromatase Inhibitors (AIs), market share of individual therapies, patient pool eligible for treatment with Aromatase Inhibitors (AIs), along with current and forecasted 7MM Aromatase Inhibitors (AIs) market size from 2020-2034 by therapies and by indication.
  • Moreover, this segment will also give a brief overview around the existing treatment paradigm of the target indications.
  • This section will include details on changing Aromatase Inhibitors (AIs) market dynamics post initiation of clinical development activities of the inhibitor.

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecasts, 2020-2023 and 2024-2034 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 27, 2024

The "Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.
  • The Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors market report provides insights around existing treatment practices in patients with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors, approved (if any) and emerging Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors, market share of individual therapies, patient pool eligible for treatment with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors, along with current and forecasted 7MM Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors market size from 2020-2034 by therapies and by indication.
  • The Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors marketed drug section will provide detailed drug profiles of already approved therapies.
  • The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors.